Build status - In Progress

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Recruiting
18 years - 99 years
All
Phase N/A
5 participants needed
1 Location

Brief description of study

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Resectable Gastric or Gastroesophageal Junction Cancer
  • Age: 18 years - 99 years
  • Gender: All

Male and Female Age 18 or older Resectable Gastric or Gastroesophageal Junction Cancer

Updated on 04 Aug 2024. Study ID: 844972

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center